• Accueil >
  • Publications >
  • Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage

Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage

1 avr. 2016Nature Communications

DOI : 10.1038/ncomms10615

Auteurs

Samar Alsafadi, Alexandre Houy, Aude Battistella, Tatiana Popova, Michel Wassef, Emilie Henry, Franck Tirode, Angelos Constantinou, Sophie Piperno-Neumann, Sergio Roman-Roman, Martin Dutertre, Marc-Henri Stern

Résumé

Abstract

Hotspot mutations in the spliceosome gene SF3B1 are reported in ∼20% of uveal melanomas. SF3B1 is involved in 3′-splice site (3′ss) recognition during RNA splicing; however, the molecular mechanisms of its mutation have remained unclear. Here we show, using RNA-Seq analyses of uveal melanoma, that the SF3B1R625/K666 mutation results in deregulated splicing at a subset of junctions, mostly by the use of alternative 3′ss. Modelling the differential junctions in SF3B1WT and SF3B1R625/K666 cell lines demonstrates that the deregulated splice pattern strictly depends on SF3B1 status and on the 3’ss-sequence context. SF3B1WT knockdown or overexpression do not reproduce the SF3B1R625/K666 splice pattern, qualifying SF3B1R625/K666 as change-of-function mutants. Mutagenesis of predicted branchpoints reveals that the SF3B1R625/K666-promoted splice pattern is a direct result of alternative branchpoint usage. Altogether, this study provides a better understanding of the mechanisms underlying splicing alterations induced by mutant SF3B1 in cancer, and reveals a role for alternative branchpoints in disease.

Membres

MARC-HENRI STERN

Directeur de recherche

EMILIE HENRY

Ingénieur d'études

MARTIN DUTERTRE

Chargé de recherche Inserm

EMILIE HENRY

Ingénieur d'études

MICHEL WASSEF

Chargé de recherche Inserm